Build Your Solution: Not Every Molecule Follows A Manual

Modern drug developers face increasing pressure as molecules grow more complex, timelines shrink, and budgets tighten. Standardized development pathways often fall short, making it essential to design strategies around the unique needs of each molecule, patient population, and program goal. A tailored development framework emphasizes foundational scientific rigor, early data generation, and iterative refinement to avoid costly rework and accelerate progress. This approach integrates formulation science, clinical insight, and flexible manufacturing capabilities to create scalable solutions that evolve with the asset as it advances toward later‑stage development.

A case example illustrates how early risk identification and parallel-path evaluation can prevent delays. Faced with a poorly flowing, highly cohesive, high‑dose molecule unsuitable for direct compression, the team used advanced characterization and compaction simulations to map manufacturability risks. Evaluating dry and wet granulation in parallel led to a robust process capable of achieving a 50% drug‑load tablet while conserving API, reducing costs, and eliminating the need for an engineering batch.